Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RLAY by emailGet an email when RLAY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RLAY, unsubscribe in one click. Privacy
📣 What RLAY Says Is Next
early 2027 · “Adverse events were consistent with those previously reported by each molecule o Phase 3 1L trial in patients with endocrine-sensitive breast cancer expected to initiate in early 2027, subject to regulatory feedback”
Company press release, Aug 6, 2026 · SEC filing
in 2026 · “ET o Triplet clinical data and frontline Phase 3 study design plan anticipated in 2026”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RLAY picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RLAY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.